Latigo Biotherapeutics Prices $345.6M IPO at $18 for Non-Opioid Pain Drug

Latigo Biotherapeutics (LTGO) priced its upsized initial public offering at $18.00 per share, selling 19,200,000 shares for $345.6 million in gross proceeds. Shares begin trading on the Nasdaq Global Select Market today, August 7, under the ticker LTGO. Goldman Sachs, Jefferies, Leerink Partners, and Guggenheim led the offering with a 30-day greenshoe option for up to 2,880,000 additional shares.

The $18 price sits at the high end of the $16-$18 range, and the upsized deal pushed gross proceeds above the initial $272 million target. At $345.6 million, Latigo is the second-largest biotech IPO of August 2026 behind Braveheart Bio ($382 million) and ahead of Attovia ($289 million). BlossomHill Therapeutics also priced a $150 million IPO today, bringing August’s biotech IPO total to over $1.1 billion across four companies.

Latigo’s lead candidate, LTG-001, is an oral Nav1.8 inhibitor for moderate to severe acute pain. Nav1.8 is a sodium channel expressed exclusively on peripheral pain-sensing neurons. Blocking it interrupts pain signaling at the source without crossing into the central nervous system, which avoids the addiction liability and sedation of opioids. LTG-001 recently reported positive topline data from a 343-patient abdominoplasty trial, meeting its primary SPID48 endpoint versus placebo.

The non-opioid pain market is enormous: over 100 million opioid prescriptions are written annually in the United States, and the FDA has been actively encouraging non-opioid alternatives. Vertex’s suzetrigine (VX-548) is already approved as the first Nav1.8 inhibitor for acute pain, validating the target. Latigo must differentiate on efficacy, particularly speed of onset and magnitude of pain reduction, to compete. A planned Phase 3 bunionectomy trial, set to start in the second half of 2026, is the next major catalyst.

A separate program, LTG-321, targets Nav1.8 for chronic osteoarthritic pain with Phase 2 data expected in the second half of 2027. That indication expands the commercial narrative well beyond acute surgical pain.

The risk: Nav1.8 inhibition is narrowly validated but not proven in large Phase 3 trials beyond suzetrigine’s initial dataset. LTG-001’s abdominoplasty data is encouraging but comes from a single Phase 2 trial with 343 patients. The Phase 3 bunionectomy trial will need consistent, clinically meaningful pain reduction to support regulatory approval and commercial uptake against an already-approved competitor with Vertex’s commercial infrastructure.

What to watch next: Phase 3 bunionectomy trial initiation and topline data. LTG-001’s ability to differentiate from suzetrigine on efficacy will determine whether Latigo can carve out a share of a market that could displace tens of millions of opioid prescriptions.